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Article / Clinical Case Report
ABSTRACT
At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more 
frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge 
to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information 
on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case 
of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development 
of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223. 
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CASE REPORT
A 57-year-old Caucasian man was referred 
to the Oncologic Center due to the diagnosis of 
prostate cancer. Besides being a smoker, he denied 
any other known disease, cardiovascular risk factors, 
use of any medication, and had no family history 
of oncologic disorders. Eight years ago, he was 
diagnosed with obstructive acute renal failure due 
to an enlarged and heterogeneous prostate detected 
by ultrasound and the total prostate-specific antigen 
(tPSA) of 250 ng/mL (reference value: 4 ng/mL). 
He was treated with percutaneous nephrostomy and 
was submitted to a transrectal core prostate biopsy 
afterward. The anatomic pathologic report showed 
a prostatic acinar adenocarcinoma Gleason 8 (4+4). 
The computed tomography (CT) scan and bone scan 
showed metastatic lesions (mainly pelvic and in the 
dorsal and lumbosacral spine). Therefore, he was 
submitted to bilateral subalbuginea orchiectomy, 
and a month after the surgery his tPSA dropped to 
26.34 ng/mL. Over the next 3 months, he presented a 
marked renal function deterioration and started regular 
hemodialytic treatment. The case was discussed in a 
multidisciplinary meeting, and it was decided to keep 
surveillance since the patient’s neoplasia was steady.
Five years after the initial symptoms, the castration-
resistant status ensued. The disease presented clinical 
progression and the patient complained of severe bone 
pain, his tPSA rose to 768 ng/mL, and a bone scan 
showed new lesions—parietal bone, right scapula, 
D4-5, 6th to 7th left costal ribs and right iliac (Figure 1).
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Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) was 1. In face of the 
disease progression, antalgic radiotherapy to the 
dorso-lumbar spine (D3-5 and D11-L4) with total doses 
of 30 Gy, and chemotherapy with docetaxel 75 mg/m2 
intravenously (21-21 days), prednisolone 10 mg/day, 
and bisphosphonate therapy with zoledronic acid 3 mg 
(with the dose adjusted to the renal failure) (21-21 days) 
were started. The latter was withdrawn after 6 months 
because of symptomatic hypocalcemia, and peripheral 
grade-1 sensory neuropathy was observed and 
considered to be an adverse event of docetaxel. 
After completing 10 cycles of chemotherapy, the disease 
seemed steady, and the patient’s tPSA was 231 ng/mL.
One year after he started the first chemotherapy, 
the patient presented a new disease progression, with 
worsening bone pain; the tPSA persistently increased 
(318 ng/mL) and the bone scan showed new lesions 
(8th to 11th costal ribs and right pubis) (Figure 2).
A second-line treatment with enzalutamide 
160 mg per day was started. No adverse events were 
observed during the whole treatment. One year later, 
the disease was stable with the tPSA 3,9 ng/mL and 
the bone scan results were unchanged. However, 
over the following 9 months, the patient presented 
new biochemical (tPSA of 217 ng/mL) and radiologic 
progression (new bone metastasis: 3rd, 6th, 7th, and 
11th right costal ribs) (Figure 3).
At the multidisciplinary meeting a third-line 
treatment with radium-223 (injections from 4-4 weeks) 
was indicated. He completed six cycles of radium-223 
in the following 8 months. No adverse events were 
reported. In the final evaluation, the patient was without 
pain and ECOG PS was 0. During the treatment, the 
tPSA determinations remained high, and at the end of 
the treatment it was 2364 ng/mL. However, the alkaline 
phosphatase (ALP) decreased and normalized at the end 
of the treatment (123 U/L) (Figure 4).
Paradoxically, the bone scan showed new lesions 
in frontal bone, 4th to 5th left costal ribs, 8th right and 
left costal ribs, sternum, and the right and left femurs, 
but less intensity of previous parietal, costal ribs and 
iliac lesions (Figure 5). The CT scan was unchanged.
The patient is currently undergoing regular 
follow-up examinations and will repeat the imaging 
revaluation scan in 3 months.
Figure 1. Bone scans in the last 4 years. Image C 
corresponds to the bone scan at the time of progression, 
with new lesions in parietal bone, right scapula, D4-5, 
6th to 7th left costal ribs and right iliac.
Figure 2. Bone scan in March 2015. New progression 
with new lesions at the 8th to 11th costal ribs and right 
pubis.
Figure 3. Bone scan in December 2016. New progression 
with new lesions in the 3rd, 6th, 7th, and 11th right 
costal ribs.
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DISCUSSION
Due to the increasing number of patients in 
hemodialysis requiring oncologic treatment with 
chemotherapy, oncologists are now expected to face 
serious dilemmas. A multidisciplinary decision involving 
oncologists, urologists, and nephrologists is crucial to 
start a chemotherapeutic regimen in these types of 
Figure 4. Behavior of the total prostate-specific antigen 
(tPSA [ng/mL]) and alkaline phosphatase (ALP [U/L]) 
determinations during and after the treatment with 
radium-223.
Figure 5. Evolution of bone scans through the years. The 
image on the right corresponds to the last evaluation, 
in September 2017, after the end of the treatment with 
radium-223.
patients. Experience with these patients is very scarce, 
as is the available published information. The scarcity 
of case reports and small case series led us to raise the 
importance of this theme.1,2 The drug selection is the 
first critical step.
The several therapeutic interactions and the need 
for treatment adjustments have to be considered. 
Regarding the docetaxel, although the main metabolic 
pathway is hepatic, and only a small part of the drug is 
excreted in the urine (less than 5-6%),3,4 some authors 
recommend the use of a reduced dose of 65 mg/m2 
(level of evidence C).4,5 However, we decided to use 
the full dose in our patient, according to the safety 
indicated by Ito et al.6
The time of the administration of the chemotherapy 
in the setting of a hemodialytic patient should also be 
taken into account to avoid drug clearance during 
the dialysis. In our case, the patient underwent 
chemotherapy after the dialysis sessions; however, 
since docetaxel is non-dialyzable,3 the treatment may 
be administered regardless of the dialysis session. 
These adaptations should be carefully carried out to 
optimize the efficacy of the selected drug.
Concerning enzalutamide, although there is scarce 
information on the dose adjustments in hemodialysis 
patients,7 caution is advised in patients with severe 
renal impairment. The drug is primarily eliminated 
by hepatic metabolism, and the renal excretion is 
insignificant.8 Our patient received the full dose of 
160 mg per day, without toxicity and with a normal 
and controlled tensional profile.
Regarding radium-223, it is considered a safe 
and well-tolerated option for castration-resistant 
prostate cancer (CRPC) patients with symptomatic 
bone metastases and no known visceral metastases. 
The drug is rapidly cleared from the blood and 
is essentially excreted into the intestine, with 
approximately 5% being excreted in the urine.9 
No dose adjustment is necessary for patients with renal 
function impairment.9
There are still some questions to be answered 
concerning the patient’s evaluation during and after 
treatment with radium-223. In this setting, the 
precise value of the tPSA and ALP as biomarkers is 
still unclear, although there is a suggestion that ALP 
better represents the therapeutic response.10 In a 
phase 3 radium-223 trial (ALSYMPCA), 87% of the 
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patients showed a decrease in ALP determination.10 
Similarly, the imaging evaluation may not accurately 
document the clinical response. Eventual changes in 
the bone scan and the CT scan have to be interpreted 
with caution, due to the flare phenomenon. The right 
timing for this evaluation is uncertain; however, 
according to the last Saint Gallen’s consensus, the 
majority of the panel (41%) considered 3-4 months 
after the beginning of the treatment, although 
27% favored the imaging study at the end, after 
completion of radium-223, and every 3-4 months 
thereafter.11,12 In our case, we decided to do it after 
the end of the treatment. The results we have are 
certainly related to a flare situation since the patient 
had an optimal clinical response.
CONCLUSION
There are many problems that oncologists find 
in patients with chronic kidney disease, especially 
regarding the safety of treatments in hemodialysis 
patients. For patients with CRPC, the exact choice 
of drug, timing, and sequence of various therapies 
remains an inexact science, essentially depending 
on the clinical history and performance status of 
the patient. In patients progressing during or after 
docetaxel chemotherapy, other safe therapeutic 
options are available on a hemodialysis program. 
Cases like this are a challenge, given the lack of 
evidence in these types of patients. For these reasons, 
pharmacokinetic and pharmacodynamic studies in 
cancer patients undergoing renal replacement therapy, 
a population that is typically excluded from clinical 
trials, should be further investigated.
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